Plasminogen activator inhibitor (PAI)-1 is an important mediator of atherosclerosis and liver fibrosis in insulin resistance. Circulating levels of PAI-1 are elevated in obese individuals, and PAI-1 mRNA is significantly higher in the livers of obese type 2 diabetic individuals than in non-obese type 2 diabetics. To address the mechanism underlying the up-regulation of hepatic PAI-1 in obesity, we tested the effects of TNF-α, an important link between obesity and insulin resistance, on PAI-1 production in the non-malignant human hepatocyte cell line, THLE-5b.
Introduction
The liver plays a central role in glucose and lipid homeostasis, and type 2 diabetes is characterized by excessive hepatic production of glucose. The long duration of diabetes and obesity causes systemic vascular complications, such as micro-and macro-angiopathy. Moreover, type 2 diabetes, together with obesity and insulin resistance, is often associated with non-alcoholic fatty liver disease (NAFLD).
Histologically, NAFLD begins as simple steatosis of hepatocytes in fatty liver, but may progress to the inflammation and fibrosis characteristic of non-alcoholic steatohepatitis (NASH). The liver is also a major source of angiogenic factors and cytokines, such as plasminogen activator inhibitor (PAI)-1 (1), vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-β (2, 3) . Many of these proteins may contribute to the development of atherosclerosis and NASH (4) .
The common pathophysiology between obesity and type 2 diabetes is insulin resistance. We recently found that fatty liver is closely associated with insulin resistance and elevated plasma levels of PAI-1 (5), in agreement with previous observations that the plasma concentration of PAI-1 is elevated in obese individuals (6) .
Moreover, plasma PAI-1 levels were found to be more closely related to liver steatosis than to adipose tissue accumulation in a murine model of genetic obesity (7) . In 4 addition, PAI-1 was shown to be important in the development of atherosclerosis (8) , as well as being a key participant in organ fibrosis (9) . Thus, PAI-1 may constitute a link between insulin resistance and its related disorders. Although the liver has been reported to be a source of PAI-1 (10, 11) , there is no in vivo or in vitro evidence of regulated PAI-1 expression in human hepatocytes.
In individuals with visceral obesity, the liver is exposed to abundant TNF-α secreted by adipocytes (12) , leading to insulin resistance. TNF-α has been reported to decrease the expression of glucose transporter 4 in adipocytes (13) . Moreover, in a human hepatoma cell line, TNF-α has been found to increase the serine phosphorylation of insulin receptor substrate-1, resulting in the reduction of insulin signaling (14).
Here, we assayed the expression of PAI-1 mRNA in the livers of individuals with type 2 diabetes by real-time PCR, and we found that obesity up-regulates hepatic PAI-1 expression in individuals with type 2 diabetes. To address the mechanism underlying the up-regulation of hepatic PAI-1 in obesity, we tested the effects of TNF-α, an important link between obesity and insulin resistance (15), on PAI-1 production and its signal transduction pathways in a non-malignant human hepatocyte cell line, THLE-5b.
We also tested the effects of a thiazolidinedione and a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin), which are potent agents in the 5 treatment of insulin resistance and dyslipidemia in obese type 2 diabetic patients, on the TNF-α-induced production of PAI-1 in THLE-5b cells.
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Materials and methods
Gene expression analysis in the liver
Liver biopsy specimens were obtained from 21 individuals with type 2 diabetes (15 males, 6 females; mean age 53 ± 2 years; mean body mass index (BMI) 24. 4 Liver biopsy specimens were histologically examined using hematoxylin-eosin and silver reticulin stains.
Cell lines and culture conditions
We used a simian virus 40 large-T (SV40-T) antigen immortalized non-malignant human hepatocyte cell line, THLE-5b. Cells at the third to fourth passage were seeded calphostin C, and genistein were purchased from Calbiochem (La Jolla, CA).
PAI-1 Assays
The concentration of PAI-1 antigens in THLE-5b cell culture supernatants was determined by ELISA (TintElize PAI-1; Biopool International, Umea, Sweden) as described (18), with a detection limit of 0.5 ng/ml. The within-and between-assay coefficients of variation were 1.9% and 2.4%, respectively.
Real-Time Quantitative PCR
Total RNA was extracted from cells using a RNeasy mini kit (QIAGEN, West Sussex, UK), as recommended by the manufacturer, and dissolved in 50 μl RNase-free water. RNA concentration was determined spectrophotometrically at 260 nm.
Complementary DNA (cDNA) was synthesized from 100 ng of total RNA as described (4) using a High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA).
The cDNA was used as a template in real time quantitative PCR, which was performed using an ABI Prism 7700 Sequence detection system (Applied Biosystems) as described (19). Primer sets and TaqMan probes for PAI-1, tissue-type plasminogen activator (tPA) and TNF-α were proprietary to Applied Biosystems. To control for variation in the amount of cDNA loaded, expression of PAI-1, tPA and TNF-α mRNA was normalized relative to the expression of an endogenous control, β-actin (β-actin TaqMan control reagent kit; Applied Biosystems). The PCR conditions were 1 cycle at 50°C for 2 min and 95°C for 10 min, followed by 50 cycles at 95°C for 15 s and 60°C for 1 min.
Statistical analysis of the data
All data are presented as means ± SEM. Differences between groups were determined using one-way ANOVA and the Kruskal-Wallis test, followed by a Fisher protected least significant test for pair-wise differences. P < 0.05 was considered statistically significant. All calculations were performed with the computer program StatView, version 4.0, for Macintosh (Abacus Concepts, Berkeley, CA).
Results
Hepatic expression of PAI-1 in patients with type 2 diabetes
Baseline characteristics of the patients are shown in Table 1 . Obese patients in the diabetic group had higher ALT values, but there were no significant differences in age, FPG, HbA 1c levels, serum levels of lipids and histological scores of the liver between obese and non-obese individuals in either group.
We found that hepatic expression of PAI-1 mRNA was significantly higher in the livers of obese type 2 diabetics than in non-obese type 2 diabetics (Fig. 1 ). There were no significant between-group differences in tPA mRNA expression.
Hepatic expression of TNF-α in patients with type 2 diabetes
Protein levels of TNF-α is found to be elevated in plasma as well as in the adipose tissue of obese subjects (20, 21) In our study, obesity up-regulated plasma levels of TNF-α and the hepatic expression of TNF-α mRNA in patients with type 2 diabetes (Fig.   2 ).
Effect of TNF-α on PAI-1 secretion from THLE-5b cells
We found that unstimulated THLE-5b cells secreted PAI-1 into the culture medium (Fig. 3A ). After incubation with 1.0 ng/ml TNF-α, PAI-1 concentrations were elevated in a time-dependent manner, peaking at 24 hours to 2.23 ± 0.15-fold of the control value (P < 0.0001 versus control). Control cultures had a PAI-1 concentration of 360 ± 40 ng/ml medium, whereas, following incubation with 2.0 ng/ml TNF-α for 24
hours, the PAI-1 concentration was 1180 ± 10 ng/ml medium. The effect of TNF-α on PAI-1 secretion was also dose-dependent, from 0.5 to 2.0 ng/ml (Fig. 3B) .
Effect of TNF-α on PAI-1 mRNA and the tPA/PAI-1 mRNA ratio in THLE-5b cells
To determine the effect of TNF-α on PAI-1 at the transcriptional level, we quantitatively evaluated PAI-1 mRNA expression by THLE-5b cells in the absence or presence of TNF-α by real-time PCR. We found that 1.0 ng/ml TNF-α induced a time-dependent increase in PAI-1 mRNA, with a maximum after 6 hours, corresponding to a 12.0 ± 4.3-fold increase relative to the control value (P < 0.05 versus control; Fig. 4A ). Since the balance between PAI-1 and tPA has been reported to determine fibrinolytic activity (22), we also assayed the effect of TNF-α on t-PA mRNA expression in these THLE-5b cells. Although TNF-α did not affect tPA mRNA levels for 24 hours (Fig. 4B) , it decreased the tPA/PAI-1 mRNA ratio in a time-dependent manner (Fig. 4C) , with a maximum effect at 6 hours (16.2 ± 7.2%, P < 0.005 versus control).
Effect of signal transduction inhibitors on TNF-α-induced PAI-1 production in hepatocytes
To determine which of the TNF-α-induced signal transduction pathways leads to PAI-1 production, we tested the effects of various pathway inhibitors on TNF-α-induced PAI-1 secretion (Fig. 5A) . The signal transduction inhibitors were used at concentrations found to be most effective and not cytotoxic in a pilot study (data not shown), as described (23). We found that the protein kinase C (PKC)
inhibitor calphostin C, the specific inhibitor of p38 mitogen-activated protein (MAP)
kinase SB 203580, the MAP kinase/extracellular signal-regulated kinase (ERK)-specific inhibitor PD98059, the protein tyrosine kinase (PTK) inhibitor genistein, and the NF-κB inhibitor emodin all reduced TNF-α-induced PAI-1 secretion in a dose-dependent manner. While calphostin C, SB203580, PD98059 and emodin partially inhibited TNF-α-induced PAI-1 secretion, genistein reduced PAI-1 secretion to the control level (P < 0.001).
To determine whether each of these inhibitors acts at the transcriptional level, we also measured steady state PAI-1 mRNA levels in these cells by real-time quantitative PCR ( Figure 5B ). We found that each of these inhibitors reduced TNF-α-induced PAI-1 mRNA in a dose-dependent manner, with a maximum effect at 6 hours, to an extent almost the same as that of PAI-1 secretion.
Effects of a thiazolidinedione and an HMG-CoA reductase inhibitor on TNF-α-induced PAI-1 secretion
When we tested the effects of a thiazolidinedione, pioglitazone, and an HMG-CoA reductase inhibitor, cerivastatin, on TNF-α induced PAI-1 secretion in THLE-5b cells, we found that each inhibited TNF-α-induced PAI-1 secretion in a dose-dependent manner (Fig. 6 ).
Cholesterol synthesis includes the conversion of HMG-CoA to mevalonic acid by the enzyme HMG-CoA reductase. We therefore tested the effects of mevalonic acid on the cerivastatin inhibition of TNF-α-stimulated PAI-1 production in THLE-5b cells.
We found that co-incubation with mevalonic acid completely reversed the inhibitory effects of cerivastatin in a dose-dependent manner (Fig. 7) .
Target of pioglitazone in the signal transduction pathway leading to TNF-α-induced PAI-1 production in hepatocytes
To identify the target of pioglitazone in the signal transduction pathways leading to TNF-α-induced PAI-1 production, we investigated the effects of the signal transduction inhibitors calphostein C, SB203580, PD98059, genistein and emodin on TNF-α-induced PAI-1 production in the presence or absence of pioglitazone (Fig. 8) .
We found that SB203580, PD98059 and genistein inhibited TNF-α-induced PAI-1 secretion in the presence of pioglitazone by 42.1 ± 2.6%, 37.7 ± 3.1% and 84.0 ± 5.6%, respectively. While SB203580, PD98059 and genistein significantly added to the inhibitory effects of pioglitazone, calphostin C and emodin did not have additive effects.
Discussion
Most in vitro studies of hepatocytes have been performed using cell lines derived from hepatomas, such as the HepG2 and Huh7 cell lines. We previously observed, however, that gene expression profiles differed among hepatocyte cell lines, especially with respect to α-fetoprotein production (24). We therefore used THLE-5b cells, a Protein levels of TNF-α is found to be elevated in plasma as well as in the adipose tissue of obese subjects (20, 21). In our study, obesity up-regulated plasma levels of TNF-α and the hepatic expression of TNF-α mRNA in patients with type 2 diabetes.
To model the regulation of PAI-1 production by the liver during insulin resistance, we assayed the in vitro effect of TNF-α on PAI-1 production by THLE-5b cells and on its signal transduction pathways. We found that TNF-α stimulated PAI-1 secretion and PAI-1 mRNA expression in these hepatocytes, suggesting that TNF-α may be an The thiazolidinedione, pioglitazone, has been found to improve glucose intolerance, insulin resistance and dyslipidemia (27) , and may inhibit the progression of atherosclerosis (28) . We previously found that troglitazone directly inhibited cytokine-induced monocyte chemoattractant protein-1 expression in human mesangial (29) and endothelial cells (30) . These findings suggested that a thiazolidinedione may inhibit atherosclerosis not only by improving glucose intolerance, insulin resistance and dyslipidemia, but also through pleiotropic effects. We have shown here that pioglitazone inhibited TNF-α-stimulated PAI-1 production in hepatocytes, similar to its effect in HUVECs (23). These effects are consistent with the clinical observation that plasma concentrations of PAI-1 in patients with type 2 diabetes are reduced after troglitazone administration (31) . Thus, thiazolidinediones may inhibit the development of diabetes-associated macro-and microangiopathy by reducing hepatic fibrinolytic activity, as well as by inhibiting the development of NASH (32, 33) .
Concerning the maximal effect of pioglitazone, pioglitazone at a dose above 10 μM seems to be pharmacological and out of range of treatment dose in a clinical setting (34) . Most in vitro experiments in the previous reports were performed by using PPAR gamma agonist at a dose under 10 μM 23, 29, 30, 35 （ ）. As shown in Figure 6 , pioglitazone at 10 μM did not abolish TNF-α-induced PAI-1 production completely.
Actually, we observed additive inhibitory effects of SB203580, PD98059 and genistein with pioglitazone on TNF-α-induced PAI-1 production. TNF-α may induce PAI-1 via both PPAR-γ-dependent and -independent pathway.
Although the target signal transduction pathway of thiazolidinediones in the regulation of PAI-1 production in hepatocytes has not yet been clarified, we have shown here that the inhibitory effects of pioglitazone on PAI-1 production are not additive with calphostin C and emodin. These findings suggest that, in hepatocytes, pioglitazone inhibits TNF-α-induced PAI-1 production via pathways involving PKC and NF-κB. We previously observed that the ERK kinase and NF-κB pathways are also involved in the effects of troglitazone on PAI-1 production in HUVECs (23). In Data are expressed as means ± SEM (n = 3; * P < 0.05; ** P < 0.001 vs. control). endogeneous control, β-actin mRNA. Data are expressed as means ± SEM (n = 3; * P < 0.05; ** P < 0.01; *** P < 0.001 versus TNF-α alone). 
